What is the difference between chronic kidney disease stage 3a (eGFR 45–59 mL/min/1.73 m²) and stage B (albuminuria category A2, urinary albumin‑to‑creatinine ratio 30–300 mg/g)?

Difference Between CKD Stage 3A and Albuminuria Category A2

Stage 3A and Category A2 represent two distinct but complementary dimensions of chronic kidney disease classification—Stage 3A describes reduced kidney filtration function (eGFR 45-59 mL/min/1.73 m²), while Category A2 describes moderately increased albumin excretion in urine (ACR 30-300 mg/g)—and both independently predict adverse outcomes including progression to kidney failure, cardiovascular disease, and mortality. 1

Understanding the CGA Classification System

The modern CKD classification uses the CGA framework where:

• C = Cause of kidney disease
• G = GFR category (G1-G5, with G3 subdivided into G3a and G3b)
• A = Albuminuria category (A1, A2, A3)

2

Stage 3A (G3a): The Filtration Component

• eGFR range: 45-59 mL/min/1.73 m²
• Represents moderate reduction in kidney filtration function
• This is a critical threshold where CKD diagnosis becomes more certain, though controversy exists when albuminuria is absent 1
• Stage 3A patients without albuminuria (A1 category) may benefit from confirmatory cystatin C testing, as approximately one-third may not have true CKD 1

Category A2: The Damage Component

• ACR range: 30-300 mg/g (formerly called "microalbuminuria")
• Represents moderately increased albumin leakage into urine
• Indicates kidney damage even when eGFR is normal or only mildly reduced
• The term "microalbuminuria" is no longer recommended—this is simply "moderately increased albuminuria" 1

Why Both Matter Independently

The critical insight is that eGFR and albuminuria provide independent prognostic information. 3 A patient can have:

1. Stage 3A with normal albuminuria (G3a A1) - moderate risk
2. Normal eGFR with A2 albuminuria (G1-2 A2) - moderate risk
3. Stage 3A with A2 albuminuria (G3a A2) - higher combined risk

The risks are additive, not multiplicative—both contribute independently to predicting kidney failure, acute kidney injury, and cardiovascular events. 3

Risk Stratification Evidence

In meta-analyses of over 1 million participants:

• Lower eGFR increases ESRD risk exponentially below 60 mL/min/1.73 m² (hazard ratio of 4 at eGFR 60, rising to 29 at eGFR 45) 3
• Higher albuminuria shows a log-linear relationship with ESRD risk (hazard ratio of 5 at ACR 30 mg/g, rising to 13 at ACR 300 mg/g) 3
• These associations persist after adjusting for cardiovascular risk factors and are independent of each other 3

Clinical Implications for Monitoring

Monitoring frequency depends on both G and A categories together:

• G3a A1: Monitor 1 time per year
• G3a A2: Monitor 2-3 times per year
• G3a A3 (severely increased albuminuria >300 mg/g): Monitor 3-4 times per year

1

Stage 3A Subdivision Matters

Stage 3B (eGFR 30-44) carries substantially higher risk than Stage 3A. In a 10-year cohort study:

• 48% of Stage 3 patients did not progress
• Stage 3B was an independent predictor of progression (HR 2.99) compared to Stage 3A
• Macroalbuminuria (A3) had HR 3.06, microalbuminuria (A2) had HR 1.99 for progression 4

This validates the subdivision of Stage 3 into 3A and 3B, as they represent distinctly different prognoses. 4

Common Pitfalls

Awareness gap: In population studies, over 80% of individuals with eGFR 30-59 mL/min/1.73 m² were unaware of having kidney disease, and even among those with both reduced eGFR and elevated albuminuria, less than half reported a diagnosis. 5 This underscores the need for systematic screening and patient education.

Variability factors: Both eGFR and ACR measurements are affected by biological and analytical variability. For ACR specifically, acute factors like volume status, infections, blood pressure changes, and heart failure exacerbations can cause fluctuations requiring repeated measurements for accurate interpretation. 6, 7

Complementary, not interchangeable: Albuminuria (ACR) and total proteinuria (UPCR) are not equivalent—ACR has greater sensitivity for detecting clinically important low-grade proteinuria and is more precise at diagnostically important concentrations. 1 However, both can serve as comparable surrogate endpoints for kidney failure risk when reduced by 30% over 2 years, though ACR may be superior in advanced CKD (eGFR <15). 8